LCN2 and breast carcinoma: After neoadjuvant chemotherapy (Morales-Valencia et al., 2022), the exposure of residual breast cancer cells to SASP can lead to the upregulation of intracellular LCN2, enhance tumor invasiveness and is related to tumor chemotherapy resistance.